润达医疗(603108) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,661,846,010.13, a decrease of 19.81% compared to ¥2,072,478,429.77 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥69,258,725.43, representing a decline of 406.40% from a profit of ¥22,603,808.03 in the previous year[4] - The basic earnings per share decreased to -¥0.11, down 375.00% from ¥0.04 in the same period last year[4] - Net profit for Q1 2025 was a loss of ¥67,863,002.26, compared to a profit of ¥47,521,987.16 in Q1 2024[17] - The total equity attributable to shareholders was ¥4,285,970,376.96 in Q1 2025, down from ¥4,354,582,007.41 in Q1 2024[14] - The company's total equity decreased to CNY 2,798,647,234.17 from CNY 2,803,495,366.03, a decline of approximately 0.2%[25] - The total comprehensive income for the period was -4,976,211.79 RMB, compared to -5,573,183.84 RMB in the prior year[26] Cash Flow - The cash flow from operating activities showed a significant improvement, with a net cash flow of ¥116,669,541.90, compared to a negative cash flow of -¥40,845,966.27 in the previous year, marking a 385.63% increase[4] - Cash inflow from operating activities was ¥2,103,042,784.86 in Q1 2025, compared to ¥2,219,850,447.83 in Q1 2024, reflecting a decrease of 5.2%[19] - The net cash flow from operating activities was -25,319,918.73 RMB, compared to -192,986,266.99 RMB in the same period last year, showing a significant reduction in cash outflow[30] - The company's cash and cash equivalents decreased to ¥945,817,244.30 from ¥1,206,525,197.67, representing a decline of about 21.56%[12] - The company's cash and cash equivalents at the end of the period were CNY 682,194,527.34, down from CNY 611,884,719.64, showing a net decrease of CNY 206,870,757.77[20] - Cash inflow from financing activities was 874,205,838.66 RMB, while cash outflow was 993,315,410.14 RMB, leading to a net cash flow of -119,109,571.48 RMB from financing[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥14,039,401,555.19, a decrease of 1.86% from ¥14,305,542,661.54 at the end of the previous year[5] - The total current assets decreased to CNY 3,350,867,336.73 from CNY 3,655,433,459.03, reflecting a decline of approximately 8.3%[23] - The total liabilities decreased to ¥9,174,000,000.00 from ¥9,500,000,000.00, reflecting a reduction of approximately 3.43%[12] - The company's total liabilities decreased to CNY 5,736,728,905.55 from CNY 6,041,694,331.77, indicating a reduction of about 5.0%[24] - The company's long-term borrowings increased to ¥787,127,257.71 in Q1 2025 from ¥661,578,715.54 in Q1 2024, representing a growth of 18.9%[14] - The company's long-term equity investments rose to ¥1,465,506,304.57 from ¥1,442,616,370.31, an increase of about 1.59%[12] Operational Challenges - The gross profit margin decreased by approximately 6% compared to the same period last year, leading to a total gross profit reduction of ¥210 million[7] - The company faced challenges due to price reductions in certain regions, impacting revenue and profit margins significantly[7] - The company is focusing on controlling costs and expenses to adapt to market changes despite the revenue decline[7] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 75,979[9] Other Financial Metrics - The weighted average return on equity was -1.60%, a decrease of 2.13 percentage points compared to 0.53% in the previous year[5] - The company's financial expenses for Q1 2025 were CNY 34,256,843.36, down from CNY 41,420,105.76 in Q1 2024, reflecting a decrease of approximately 17.4%[25] - The company's goodwill remained stable at ¥1,982,679,226.06, unchanged from the previous period[12] - The total non-current assets slightly decreased to ¥5,094,706,515.56 from ¥5,102,522,533.62, indicating a minor decline of approximately 0.15%[12] - The company's other comprehensive income after tax for Q1 2025 was ¥61,323.97, compared to ¥1,025,645.62 in Q1 2024[18] - The company reported an investment income of CNY 81,856,466.19 for Q1 2025, significantly higher than CNY 24,883,601.31 in Q1 2024, marking an increase of approximately 228.5%[25] Accounting Standards - The company is not applying new accounting standards or interpretations starting from 2025[32]